XTL Biopharmaceuticals Ltd.

What they do

XTL Biopharmaceuticals, based in Israel, is a clinical-stage biopharmaceutical company with a pipeline primarily derived from its acquisition of Psyga Bio Ltd. It seeks to identify and acquire or in-license product opportunities, with a current focus on developing its acquired assets. The company is a non-accelerated filer and is listed on the Nasdaq Capital Market and the Tel Aviv Stock Exchange.

Revenue drivers

• No commercial products — As of the fiscal year ended December 31, 2025, the company has no marketed products and does not generate revenue from product sales.
• Development stage pipeline — Revenue potential is tied to future commercialization of product candidates, primarily those from the Psyga Bio acquisition, but no milestone or royalty revenue is currently recognized.

Recent performance

The company reported no revenue for the fiscal year ended December 31, 2025. It issued 946,243,356 ordinary shares as of the end of the period, excluding 372,957,973 dormant shares. The company highlighted its ability to continue operating as a going concern as a key risk factor, indicating limited liquidity. No specific financial results (e.g., net loss or cash position) were provided in the excerpt.

Strategy

The company's stated strategy includes continuing to operate as a going concern and raising additional capital to satisfy working capital requirements. It plans to identify and consummate potential acquisition targets, with the Psyga Bio acquisition being a recent example. Management also focuses on in-licensing, partnering, and acquiring new product opportunities to advance its pipeline.

Risks

• Going concern uncertainty — The company's ability to continue operating is in doubt, as management lists it as a top risk factor in the forward-looking statements.
• Delisting risk — The company's securities could be delisted from the Nasdaq Capital Market or the Tel Aviv Stock Exchange, which could impair liquidity and shareholder value.
• Dilution from future fundraising — Future issuances of securities could significantly dilute existing shareholders.
• Geopolitical risk in Israel — Operations and financial results could be adversely affected by political, economic, and military instability in Israel and the Middle East.

Outlook

Management expects to continue pursuing acquisitions and in-licensing opportunities, but acknowledges significant uncertainty regarding liquidity. The company will likely need to raise additional capital to fund operations and development. The accuracy of financial forecasts is uncertain, and the ability to execute its complete business objectives is not assured.